Industry > Technology Transfer > HandyLab

HandyLab

handylab logo
Founded: 2000
Founders: Kalyan Handique, Sundaresh Brahmasandra
Product/Service: Novel clinical diagnostic testing products to improve infectious disease testing
Acquired By: Acquired by BD Nov 20, 2009
Website: handylab.com

HandyLab is dedicated to the development, manufacture and sale of novel molecular diagnostic products. HandyLab's proprietary platform reduces the time, cost and complexity of testing while improving the quality of results. Using patented real time microfluidic PCR technology, HandyLab's products are positioned to decentralize nucleic acid testing. .[BD Website, News and Events]


In the News

bd logo Nov 20, 2009

BD Completes Acquisition of HandyLab, Inc.

Franklin Lakes, NJ — BD (Becton, Dickinson and Company) (NYSE:BDX) today announced the completion of its acquisition of HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms.

In May 2009, BD and HandyLab announced an exclusive agreement for BD to develop and commercialize molecular assays on the HandyLab Jaguar™ platform, the first fully integrated molecular diagnostic system to provide hands-off operation, incorporating clinical sample preparation, nucleic acid extraction, and microfluidic real-time polymerase chain reaction (PCR) amplification and detection in a simple bench-top system. The self-contained workstation is designed to accommodate both batch workflows and on-demand testing for maximum lab efficiency and flexibility.


Expand this Article   Hide

© Becton, Dickinson and Company Press Release. Colleen T. White, Corporate Communications: (201) 847-5369, colleen_white@bd.com and Patricia A. Spinella, Investor Relations: (201) 847-5453, patricia_spinella@bd.com


tech transfer logoTech Transfer Success Story

In a birthing suite, a woman goes into labor. The nurse on duty quickly takes a vaginal swab, places it in a syringe containing a small amount of buffer solution, and injects the liquid into a port on a small hand-held instrument. Then, by pressing a single button, she triggers a fully automated DNA analysis. In less than 30 minutes, she'll know whether or not the baby could be exposed to Grade B Streptococcus (GBS), a potentially fatal pathogen-treatable if detected early-that's carried by up to 20 percent of all new mothers.


Expand this Article   Hide

© UM Tech Transfer